ADCT
Adc Therapeutics SA

1,247
Mkt Cap
$445.06M
Volume
758,387.00
52W High
$4.80
52W Low
$1.05
PE Ratio
-2.49
ADCT Fundamentals
Price
$3.61
Prev Close
$3.80
Open
$3.76
50D MA
$3.82
Beta
1.49
Avg. Volume
1.87M
EPS (Annual)
-$1.62
P/B
-1.71
Rev/Employee
$267,309.43
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 47.2%
ADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 3,573,570 shares, a decline of...
MarketBeat·8d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·9d ago
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Agenus (AGEN) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. One...
MarketBeat·11d ago
News Placeholder
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025...
PR Newswire·16d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·16d ago
News Placeholder
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, Jan. 2, 2026 LAUSANNE, Switzerland, Jan. 2, 2026...
PR Newswire·22d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·23d ago
News Placeholder
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·26d ago
<
1
2
...
>

Latest ADCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.